Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Sleep Initiation and Maintenance Disorders: HELP
Articles by Joann E. Manson
Based on 6 articles published since 2008

Between 2008 and 2019, JoAnn Manson wrote the following 6 articles about Sleep Initiation and Maintenance Disorders.
+ Citations + Abstracts
1 Article Association of sleep disturbance and sexual function in postmenopausal women. 2017

Kling, Juliana M / Manson, JoAnn E / Naughton, Michelle J / Temkit, M'hamed / Sullivan, Shannon D / Gower, Emily W / Hale, Lauren / Weitlauf, Julie C / Nowakowski, Sara / Crandall, Carolyn J. ·1Division of Women's Health, Mayo Clinic, Scottsdale, AZ 2Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 3Division of Population Sciences, Department of Internal Medicine, Ohio State University, Columbus, OH 4Division of Health Sciences Research, Mayo Clinic, Scottsdale, AZ 5Division of Endocrinology, Medstar Washington Hospital Center and Georgetown University, Washington, DC 6Department of Epidemiology and Ophthalmology, Wake Forest School of Medicine, Winston-Salem, NC 7Program in Public Health, Department of Family, Population, and Preventive Medicine, Stony Brook University, Stony Brook, NY 8Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 9Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA 10Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX 11Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA. ·Menopause · Pubmed #28141665.

ABSTRACT: OBJECTIVE: Sleep disturbance and sexual dysfunction are common in menopause; however, the nature of their association is unclear. The present study aimed to determine whether sleep characteristics were associated with sexual activity and sexual satisfaction. METHODS: Sexual function in the last year and sleep characteristics (past 4 wk) were assessed by self-report at baseline for 93,668 women age 50 to 79 years enrolled in the Women's Health Initiative (WHI) Observational Study (OS). Insomnia was measured using the validated WHI Insomnia Rating Scale. Sleep-disordered breathing (SDB) risk was assessed using questions adapted from the Berlin Questionnaire. Using multivariate logistic regression, we examined cross-sectional associations between sleep measures and two indicators of sexual function: partnered sexual activity and sexual satisfaction within the last year. RESULTS: Fifty-six percent overall reported being somewhat or very satisfied with their current sexual activity, and 52% reported partnered sexual activity within the last year. Insomnia prevalence was 31%. After multivariable adjustment, higher insomnia scores were associated with lower odds of sexual satisfaction (yes/no) (odds ratio [OR] 0.92, 95% CI, 0.87-0.96). Short sleep duration (<7-8 h) was associated with lower odds of partnered sexual activity (yes/no) (≤5 h, OR 0.88, 95% CI, 0.80-0.96) and less sexual satisfaction (≤5 h, OR 0.88, 95% CI, 0.81-0.95). CONCLUSIONS: Shorter sleep durations and higher insomnia scores were associated with decreased sexual function, even after adjustment for potential confounders, suggesting the importance of sufficient, high-quality sleep for sexual function. Longitudinal investigation of sleep and its impact on sexual function postmenopause will clarify this relationship.

2 Article Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study. 2017

Santoro, Nanette / Allshouse, Amanda / Neal-Perry, Genevieve / Pal, Lubna / Lobo, Rogerio A / Naftolin, Frederick / Black, Dennis M / Brinton, Eliot A / Budoff, Matthew J / Cedars, Marcelle I / Dowling, N Maritza / Dunn, Mary / Gleason, Carey E / Hodis, Howard N / Isaac, Barbara / Magnani, Maureen / Manson, JoAnn E / Miller, Virginia M / Taylor, Hugh S / Wharton, Whitney / Wolff, Erin / Zepeda, Viola / Harman, S Mitchell. ·1Department of Obstetrics & Gynecology 2Department of Biostatistics, University of Colorado School of Medicine, Aurora, CO 3Department of Obstetrics, Gynecology & Women's Health and Neurosciences, Albert Einstein College of Medicine, Bronx, NY 4Department of Obstetrics & Gynecology, Yale University School of Medicine, New Haven, CT 5Department of Obstetrics & Gynecology, Columbia University College of Physicians and Surgeons, New York, NY 6Department of Obstetrics & Gynecology, New York University School of Medicine, New York, NY 7Department of Epidemiology & Biostatistics, University of California at San Francisco, San Francisco, CA 8Utah Foundation for Biomedical Research, Salt Lake City, UT 9Department of Cardiology, Los Angeles Biomedical Research Institute at Harbor UCLA, Torrance, CA 10Department of Obstetrics & Gynecology, University of California at San Francisco, San Francisco, CA 11Departments of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI 12Kronos Longevity Research Institute, Phoenix, AZ 13Department of Medicine and Public Health, University of Wisconsin, Madison, WI 14Atherosclerosis Research Unit, University of Southern California, Los Angeles, CA 15Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 16Departments of Surgery and Physiology & Biomedical Engineering, Mayo Clinic, Rochester, MN 17Department of Neurology, Emory University, Atlanta, GA 18Department of Reproductive Biology and Medicine, National Institutes of Health, Bethesda, MD 19Department of Medicine, Endocrine Division, Phoenix VA Health Care System, Phoenix, AZ. ·Menopause · Pubmed #27779568.

ABSTRACT: OBJECTIVE: The objective of the present study was to compare the efficacy of two forms of menopausal hormone therapy in alleviating vasomotor symptoms, insomnia, and irritability in early postmenopausal women during 4 years. METHODS: A total of 727 women, aged 42 to 58, within 3 years of their final menstrual period, were randomized to receive oral conjugated estrogens (o-CEE) 0.45 mg (n = 230) or transdermal estradiol (t-E2) 50 μg (n = 225; both with micronized progesterone 200 mg for 12 d each mo), or placebos (PBOs; n = 275). Menopausal symptoms were recorded at screening and at 6, 12, 24, 36, and 48 months postrandomization. Differences in proportions of women with symptoms at baseline and at each follow-up time point were compared by treatment arm using exact χ tests in an intent-to-treat analysis. Differences in treatment effect by race/ethnicity and body mass index were tested using generalized linear mixed effects modeling. RESULTS: Moderate to severe hot flashes (from 44% at baseline to 28.3% for PBO, 7.4% for t-E2, and 4.2% for o-CEE) and night sweats (from 35% at baseline to 19% for PBO, 5.3% for t-E2, and 4.7% for o-CEE) were reduced significantly by 6 months in women randomized to either active hormone compared with PBO (P < 0.001 for both symptoms), with no significant differences between the active treatment arms. Insomnia and irritability decreased from baseline to 6 months postrandomization in all groups. There was an intermittent reduction in insomnia in both active treatment arms versus PBO, with o-CEE being more effective than PBO at 36 and 48 months (P = 0.002 and 0.05) and t-E2 being more effective than PBO at 48 months (P = 0.004). Neither hormone treatment significantly affected irritability compared with PBO. Symptom relief for active treatment versus PBO was not significantly modified by body mass index or race/ethnicity. CONCLUSIONS: Recently postmenopausal women had similar and substantial reductions in hot flashes and night sweats with lower-than-conventional doses of oral or transdermal estrogen. These reductions were sustained during 4 years. Insomnia was intermittently reduced compared with PBO for both hormone regimens.

3 Article Sleep duration, cognitive decline, and dementia risk in older women. 2016

Chen, Jiu-Chiuan / Espeland, Mark A / Brunner, Robert L / Lovato, Laura C / Wallace, Robert B / Leng, Xiaoyan / Phillips, Lawrence S / Robinson, Jennifer G / Kotchen, Jane M / Johnson, Karen C / Manson, JoAnn E / Stefanick, Marcia L / Sarto, Gloria E / Mysiw, W Jerry. ·Department of Preventive Medicine, University of Southern California, Keck School of Medicine, Los Angeles, CA, USA. Electronic address: jcchen@usc.edu. · Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA. · Department of Family and Community Medicine, University of Nevada School of Medicine, Reno, NV, USA. · Departments of Epidemiology & Medicine, University of Iowa, Iowa City, IA, USA. · Atlanta VA Medical Center and Division of Endocrinology, Emory University School of Medicine, Atlanta, GA, USA. · Department of Population Health, Medical College of Wisconsin, Milwaukee, WI, USA. · Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN, USA. · Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. · Department of Medicine, Stanford University, Stanford, CA, USA. · University of Wisconsin Center for Women's Health Research, Madison, WI, USA. · Department of Physical Medicine and Rehabilitation, Ohio State University, Columbus, OH, USA. ·Alzheimers Dement · Pubmed #26086180.

ABSTRACT: INTRODUCTION: Consistent evidence linking habitual sleep duration with risks of mild cognitive impairment (MCI) and dementia is lacking. METHODS: We conducted a prospective study on 7444 community-dwelling women (aged 65-80 y) with self-reported sleep duration, within the Women's Health Initiative Memory Study in 1995-2008. Incident MCI/dementia cases were ascertained by validated protocols. Cox models were used to adjust for multiple sociodemographic and lifestyle factors, depression, cardiovascular disease (CVD), and other clinical characteristics. RESULTS: We found a statistically significant (P = .03) V-shaped association with a higher MCI/dementia risk in women with either short (≤6 hours/night) or long (≥8 hours/night) sleep duration (vs. 7 hours/night). The multicovariate-adjusted hazard for MCI/dementia was increased by 36% in short sleepers irrespective of CVD, and by 35% in long sleepers without CVD. A similar V-shaped association was found with cognitive decline. DISCUSSION: In older women, habitual sleep duration predicts the future risk for cognitive impairments including dementia, independent of vascular risk factors.

4 Article Effects of estradiol and venlafaxine on insomnia symptoms and sleep quality in women with hot flashes. 2015

Ensrud, Kristine E / Guthrie, Katherine A / Hohensee, Chancellor / Caan, Bette / Carpenter, Janet S / Freeman, Ellen W / LaCroix, Andrea Z / Landis, Carol A / Manson, JoAnn / Newton, Katherine M / Otte, Julie / Reed, Susan D / Shifren, Jan L / Sternfeld, Barbara / Woods, Nancy F / Joffe, Hadine. ·Department of Medicine and Division of Epidemiology & Community Health, University of Minnesota, Minneapolis, MN: Center for Chronic Disease Outcomes Research, Minneapolis VA Health Care System, Minneapolis, MN. · Fred Hutchinson Cancer Research Center, Seattle WA. · Division of Research, Kaiser Permanente, Oakland, CA. · School of Nursing, Indiana University, Indianapolis, IN. · Departments of Obstetrics, Gynecology and Psychiatry, University of Pennsylvania, Philadelphia, PA. · Department of Biobehavioral Nursing and Health Systems, University of Washington, Seattle, WA. · Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. · Group Health Research Institute, Seattle WA. · Department of Medicine, University of Washington, Seattle, WA. · Department of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. · Department of Psychiatry, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA. ·Sleep · Pubmed #25325454.

ABSTRACT: STUDY OBJECTIVES: Determine effects of low-dose estradiol and low-dose venlafaxine on self-reported sleep measures in menopausal women with hot flashes. DESIGN: 3-arm double-blind randomized trial. Participants assigned in a 2:2:3 ratio to 17β estradiol 0.5 mg/day (n = 97), venlafaxine XR 75 mg/day (n = 96), or placebo (n = 146) for 8 weeks. SETTING: Academic research centers. PARTICIPANTS: 339 community-dwelling perimenopausal and postmenopausal women with ≥2 bothersome hot flashes per day. MEASUREMENTS AND RESULTS: Insomnia symptoms (Insomnia Severity Index [ISI]) and sleep quality (Pittsburgh Sleep Quality Index [PSQI]) at baseline, week 4 and 8; 325 women (96%) provided ISI data and 312 women (92%) provided PSQI data at baseline and follow-up. At baseline, mean (SD) hot flash frequency was 8.1/day (5.3), mean ISI was 11.1 (6.0), and mean PSQI was 7.5 (3.4). Mean (95% CI) change from baseline in ISI at week 8 was -4.1 points (-5.3 to -3.0) with estradiol, -5.0 points (-6.1 to -3.9) with venlafaxine, and -3.0 points (-3.8 to -2.3) with placebo (P overall treatment effect vs. placebo 0.09 for estradiol and 0.007 for venlafaxine). Mean (95% CI) change from baseline in PSQI at week 8 was -2.2 points (-2.8 to -1.6) with estradiol, -2.3 points (-2.9 to -1.6) with venlafaxine, and -1.2 points (-1.7 to -0.8) with placebo (P overall treatment effect vs. placebo 0.04 for estradiol and 0.06 for venlafaxine). CONCLUSIONS: Among perimenopausal and postmenopausal women with hot flashes, both low dose oral estradiol and low-dose venlafaxine compared with placebo modestly reduced insomnia symptoms and improved subjective sleep quality. CLINICAL TRIAL REGISTRATION: NCT01418209 at www.clinicaltrials.gov.

5 Article Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial. 2014

Cohen, Lee S / Joffe, Hadine / Guthrie, Katherine A / Ensrud, Kristine E / Freeman, Marlene / Carpenter, Janet S / Learman, Lee A / Newton, Katherine M / Reed, Susan D / Manson, Joann E / Sternfeld, Barbara / Caan, Bette / Freeman, Ellen W / LaCroix, Andrea Z / Tinker, Lesley F / Booth-Laforce, Cathryn / Larson, Joseph C / Anderson, Garnet L. ·From the 1Massachusetts General Hospital, Boston, MA; 2MsFLASH Data Coordinating Center, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA; 3VA Medical Center, University of Minnesota, Minneapolis, MN; 4School of Nursing, Indiana University, Indianapolis, IN; 5Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN; 6Group Health Research Institute, Group Health Cooperative, Seattle, WA; 7Departments of Obstetrics/Gynecology and Epidemiology, University of Washington School of Medicine, Seattle, WA; 8Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; 9Division of Research, Kaiser Permanente Medical Program of Northern California, Oakland, CA; 10Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA; and 11School of Nursing, University of Washington, Seattle, WA. ·Menopause · Pubmed #23982113.

ABSTRACT: OBJECTIVE: This study aims to determine the efficacy and tolerability of omega-3 fatty acids in reducing vasomotor symptoms (VMS) frequency and bother in perimenopausal and postmenopausal women. METHODS: This study was a 12-week, three-by-two factorial, randomized controlled trial. Eligible women were randomized to a double-blind comparison of omega-3 (n = 177) or placebo (n = 178) capsules, and simultaneously to yoga (n = 107), aerobic exercise (n = 106), or their usual physical activity (n = 142). Participants received 1.8 g of omega-3 daily for 12 weeks. Each capsule contained ethyl eicosapentaenoic acid (425 mg), docosahexaenoic acid (100 mg), and other omega-3s (90 mg). Primary outcomes were VMS frequency and bother. Secondary outcomes included sleep quality (Pittsburgh Sleep Quality Index), insomnia symptoms (Insomnia Severity Index), depressive symptoms (Physician's Health Questionnaire-8), and anxiety (Generalized Anxiety Disorder-7). RESULTS: The mean baseline frequency of VMS per day was 7.6 (95% CI, 7.0 to 8.2). After 12 weeks, the reduction in VMS frequency with omega-3 (-2.5; 95% CI, -3.0 to -1.9) did not differ significantly from that with placebo (-2.7; 95% CI, -3.3 to -2.2), with a relative difference of 0.3 fewer hot flashes per day (95% CI, -0.5 to 1.0; P = 0.28). Changes in VMS bother at 12 weeks were also similar between groups, with no relative difference on a four-point scale (95% CI, -0.1 to 0.2; P = 0.36). Omega-3s compared with placebo showed no improvement in self-reported sleep or mood (P > 0.09 for all comparisons). CONCLUSIONS: Among healthy, sedentary perimenopausal and postmenopausal women, a 12-week treatment with omega-3 does not improve VMS frequency, VMS bother, sleep, or mood compared with placebo.

6 Article Association between sleep and breast cancer incidence among postmenopausal women in the Women's Health Initiative. 2013

Vogtmann, Emily / Levitan, Emily B / Hale, Lauren / Shikany, James M / Shah, Neomi A / Endeshaw, Yohannes / Lewis, Cora E / Manson, Joann E / Chlebowski, Rowan T. ·Department of Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL. ·Sleep · Pubmed #24082303.

ABSTRACT: STUDY OBJECTIVES: To determine whether the duration of sleep, sleep quality, insomnia, or sleep disturbance was associated with incident breast cancer in the Women's Health Initiative (WHI). DESIGN: Prospective cohort study. SETTING: Women enrolled in one of the Clinical Trial (CT) arms or the Observational Study (OS) from the WHI conducted in the United States. PARTICIPANTS: This study included 110,011 women age 50 to 79 years with no history of cancer. MEASUREMENTS AND RESULTS: Typical sleep duration, sleep quality, and other self-reported sleep measures over the past 4 weeks were assessed during the screening visits for both the CT and OS participants. The presence of insomnia and level of sleep disturbance was calculated from an index of the WHI Insomnia Rating Scale. The outcome for this study was primary, invasive breast cancer. A total of 5,149 incident cases of breast cancer were identified in this study. No statistically significant associations were found between sleep duration, sleep quality, insomnia, or level of sleep disturbance with the risk of breast cancer after multivariable adjustment. A positive trend was observed for increasing sleeping duration with the risk of estrogen receptor positive breast cancer, but the association estimates for each sleep duration category were weak and nonsignificant. CONCLUSIONS: This study does not provide strong support for an association between self-reported sleep duration, sleep quality, insomnia, or sleep disturbance with the risk of breast cancer.